American Bio Medica Corporation (ABMC)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | 1.04 Million USD | -34.05% |
| 2021 | 1.72 Million USD | -7.1% |
| 2020 | 1.85 Million USD | 4.61% |
| 2019 | 1.77 Million USD | -13.32% |
| 2018 | 2.05 Million USD | -11.18% |
| 2017 | 2.3 Million USD | -15.98% |
| 2016 | 2.74 Million USD | -10.84% |
| 2015 | 3.08 Million USD | -6.04% |
| 2014 | 3.27 Million USD | -30.28% |
| 2013 | 4.7 Million USD | 10.06% |
| 2012 | 4.27 Million USD | 6.24% |
| 2011 | 4.02 Million USD | -13.36% |
| 2010 | 4.64 Million USD | -3.03% |
| 2009 | 4.78 Million USD | -18.69% |
| 2008 | 5.88 Million USD | -10.63% |
| 2007 | 6.58 Million USD | 0.53% |
| 2006 | 6.55 Million USD | 2.62% |
| 2005 | 6.38 Million USD | 2.19% |
| 2004 | 6.24 Million USD | 1.96% |
| 2003 | 6.12 Million USD | 20.46% |
| 2002 | 5.08 Million USD | 0.0% |
| 2001 | - USD | -100.0% |
| 2000 | 6.12 Million USD | 13.46% |
| 1999 | 5.4 Million USD | -3.55% |
| 1998 | 5.6 Million USD | 438.97% |
| 1997 | 1.03 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q2 | - USD | -100.0% |
| 2023 Q1 | 286 Thousand USD | 13.49% |
| 2023 Q3 | - USD | 0.0% |
| 2022 Q2 | 274 Thousand USD | -23.68% |
| 2022 Q1 | 359 Thousand USD | 4.06% |
| 2022 FY | 1.13 Million USD | -34.05% |
| 2022 Q4 | 252 Thousand USD | -0.4% |
| 2022 Q3 | 253 Thousand USD | -7.66% |
| 2021 Q4 | 345 Thousand USD | -11.31% |
| 2021 FY | 1.72 Million USD | -7.1% |
| 2021 Q1 | 614 Thousand USD | 45.15% |
| 2021 Q2 | 380 Thousand USD | -38.11% |
| 2021 Q3 | 389 Thousand USD | 2.37% |
| 2020 FY | 1.85 Million USD | 4.61% |
| 2020 Q2 | 566 Thousand USD | 22.78% |
| 2020 Q3 | 407 Thousand USD | -28.09% |
| 2020 Q1 | 461 Thousand USD | 16.12% |
| 2020 Q4 | 423 Thousand USD | 3.93% |
| 2019 Q1 | 480 Thousand USD | 3.45% |
| 2019 Q2 | 461 Thousand USD | -3.96% |
| 2019 Q3 | 440 Thousand USD | -4.56% |
| 2019 Q4 | 397 Thousand USD | -9.77% |
| 2019 FY | 1.77 Million USD | -13.32% |
| 2018 FY | 2.05 Million USD | -11.18% |
| 2018 Q4 | 464 Thousand USD | -6.45% |
| 2018 Q3 | 496 Thousand USD | -2.94% |
| 2018 Q1 | 578 Thousand USD | 9.26% |
| 2018 Q2 | 511 Thousand USD | -11.59% |
| 2017 Q1 | 632 Thousand USD | -4.24% |
| 2017 Q3 | 561 Thousand USD | -4.27% |
| 2017 Q4 | 529 Thousand USD | -5.7% |
| 2017 FY | 2.3 Million USD | -15.98% |
| 2017 Q2 | 586 Thousand USD | -7.28% |
| 2016 Q4 | 660 Thousand USD | -1.64% |
| 2016 FY | 2.74 Million USD | -10.84% |
| 2016 Q1 | 721 Thousand USD | -0.55% |
| 2016 Q2 | 695 Thousand USD | -3.61% |
| 2016 Q3 | 671 Thousand USD | -3.45% |
| 2015 Q4 | 725 Thousand USD | 0.14% |
| 2015 Q2 | 880 Thousand USD | 16.87% |
| 2015 Q3 | 724 Thousand USD | -17.73% |
| 2015 FY | 3.08 Million USD | -6.04% |
| 2015 Q1 | 753 Thousand USD | -11.31% |
| 2014 FY | 3.27 Million USD | -30.28% |
| 2014 Q1 | 815 Thousand USD | -31.05% |
| 2014 Q2 | 768 Thousand USD | -5.77% |
| 2014 Q4 | 849 Thousand USD | 0.24% |
| 2014 Q3 | 847 Thousand USD | 10.29% |
| 2013 Q3 | 1.19 Million USD | 1.02% |
| 2013 Q4 | 1.18 Million USD | -0.84% |
| 2013 FY | 4.7 Million USD | 10.06% |
| 2013 Q2 | 1.18 Million USD | 2.79% |
| 2013 Q1 | 1.14 Million USD | 20.84% |
| 2012 Q4 | 950 Thousand USD | -15.18% |
| 2012 Q3 | 1.12 Million USD | 4.48% |
| 2012 Q2 | 1.07 Million USD | -5.22% |
| 2012 Q1 | 1.13 Million USD | 16.6% |
| 2012 FY | 4.27 Million USD | 6.24% |
| 2011 Q1 | 1.13 Million USD | 2.43% |
| 2011 FY | 4.02 Million USD | -13.36% |
| 2011 Q3 | 940 Thousand USD | -3.69% |
| 2011 Q4 | 970 Thousand USD | 3.19% |
| 2011 Q2 | 976 Thousand USD | -14.08% |
| 2010 Q2 | 1.23 Million USD | 5.9% |
| 2010 FY | 4.64 Million USD | -3.03% |
| 2010 Q4 | 1.1 Million USD | -1.33% |
| 2010 Q3 | 1.12 Million USD | -9.28% |
| 2010 Q1 | 1.17 Million USD | 3.63% |
| 2009 Q3 | 1.2 Million USD | -8.82% |
| 2009 FY | 4.78 Million USD | -18.69% |
| 2009 Q1 | 1.12 Million USD | -11.71% |
| 2009 Q2 | 1.32 Million USD | 18.08% |
| 2009 Q4 | 1.12 Million USD | -6.62% |
| 2008 Q1 | 1.58 Million USD | 0.32% |
| 2008 FY | 5.88 Million USD | -10.63% |
| 2008 Q2 | 1.65 Million USD | 3.96% |
| 2008 Q4 | 1.27 Million USD | -7.36% |
| 2008 Q3 | 1.37 Million USD | -16.89% |
| 2007 Q3 | 1.63 Million USD | -11.21% |
| 2007 Q4 | 1.58 Million USD | -2.94% |
| 2007 FY | 6.58 Million USD | 0.53% |
| 2007 Q1 | 1.53 Million USD | -4.55% |
| 2007 Q2 | 1.83 Million USD | 19.9% |
| 2006 FY | 6.55 Million USD | 2.62% |
| 2006 Q1 | 1.61 Million USD | 4.75% |
| 2006 Q2 | 1.65 Million USD | 2.92% |
| 2006 Q3 | 1.67 Million USD | 1.27% |
| 2006 Q4 | 1.6 Million USD | -4.29% |
| 2005 Q3 | 1.68 Million USD | 6.36% |
| 2005 Q4 | 1.53 Million USD | -9.0% |
| 2005 Q2 | 1.58 Million USD | 1.02% |
| 2005 Q1 | 1.57 Million USD | 10.16% |
| 2005 FY | 6.38 Million USD | 2.19% |
| 2004 Q1 | 1.68 Million USD | 19.93% |
| 2004 Q4 | 1.42 Million USD | -7.7% |
| 2004 Q2 | 1.58 Million USD | -5.7% |
| 2004 Q3 | 1.54 Million USD | -2.71% |
| 2004 FY | 6.24 Million USD | 1.96% |
| 2003 Q2 | 1.48 Million USD | -0.07% |
| 2003 Q1 | 1.48 Million USD | 28.28% |
| 2003 Q4 | 1.4 Million USD | -19.62% |
| 2003 Q3 | 1.74 Million USD | 17.55% |
| 2003 FY | 6.12 Million USD | 20.46% |
| 2002 FY | 5.08 Million USD | 0.0% |
| 2002 Q1 | 1.29 Million USD | 0.0% |
| 2002 Q2 | 1.23 Million USD | -4.62% |
| 2002 Q3 | 1.46 Million USD | 17.93% |
| 2002 Q4 | 1.16 Million USD | -20.55% |
| 2001 FY | - USD | -100.0% |
| 2001 Q3 | 1.77 Million USD | 36.74% |
| 2001 Q2 | 1.3 Million USD | -34.75% |
| 2001 Q1 | 1.99 Million USD | 21.44% |
| 2000 Q2 | 1.72 Million USD | -30.69% |
| 2000 FY | 6.12 Million USD | 13.46% |
| 2000 Q3 | 1.94 Million USD | 13.07% |
| 2000 Q1 | 2.48 Million USD | 80.58% |
| 2000 Q4 | 1.64 Million USD | -15.62% |
| 1999 Q2 | 1.15 Million USD | -32.09% |
| 1999 Q3 | 1.11 Million USD | -2.78% |
| 1999 FY | 5.4 Million USD | -3.55% |
| 1999 Q4 | 1.37 Million USD | 22.88% |
| 1999 Q1 | 1.69 Million USD | 7.62% |
| 1998 Q3 | 1.03 Million USD | -6.28% |
| 1998 Q4 | 1.57 Million USD | 52.91% |
| 1998 FY | 5.6 Million USD | 438.97% |
| 1998 Q1 | 3.7 Million USD | 311.11% |
| 1998 Q2 | 1.09 Million USD | -70.3% |
| 1997 Q4 | 900 Thousand USD | 0.0% |
| 1997 FY | 1.03 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Arrayit Corporation | 6.19 Million USD | 83.074% |
| Atlantic International Corp. | 5.57 Million USD | 81.195% |
| Biocept, Inc. | 29.4 Million USD | 96.432% |
| Bioqual, Inc. | 7.44 Million USD | 85.917% |
| CardioGenics Holdings Inc | 772.14 Thousand USD | -35.856% |
| DermTech, Inc. | 104.01 Million USD | 98.991% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 166.5 Million USD | 99.37% |
| HTG Molecular Diagnostics, Inc. | 22.62 Million USD | 95.363% |
| iMD Companies, Inc. | 151.8 Thousand USD | -591.0% |
| IDenta Corp. | 662.97 Thousand USD | -58.226% |
| Interpace Biosciences, Inc. | 20.23 Million USD | 94.815% |
| Integrative Health Technologies, Inc. | 38.88 Thousand USD | -2597.976% |
| InVitro International | 661.32 Thousand USD | -58.621% |
| Lumos Diagnostics Holdings Limited | 7.09 Million USD | 85.221% |
| Many Bright Ideas Technologies Inc. | 58.11 Thousand USD | -1705.135% |
| Medical Imaging Corp. | 1.91 Million USD | 45.141% |
| NovelStem International Corp. | 3.53 Million USD | 70.349% |
| Optigenex Inc. | 1.28 Million USD | 18.548% |
| PharmChem, Inc. | 2.93 Million USD | 64.213% |
| Proteome Sciences plc | 3.26 Million USD | 67.901% |
| Response Genetics, Inc | 25.31 Million USD | 95.857% |
| Rennova Health, Inc. | 7.67 Million USD | 86.337% |
| RushNet, Inc. | 1.78 Million USD | 41.374% |
| ScreenPro Security Inc. | 3.23 Million USD | 67.613% |
| Stella Diagnostics Inc. | 11.42 Million USD | 90.82% |
| StageZero Life Sciences Ltd. | 7.34 Million USD | 85.714% |
| Todos Medical Ltd. | 14.05 Million USD | 92.538% |